STERIS plc(STE)Earnings, Financials & Key Ratios

STE•NYSE

$214.52

$21.09B mkt cap·34.6× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryDevice suppliers, distribution, and services

AboutSTERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.Show more

Revenue$5.46B+6.2%
EBITDA$1.34B-4.2%
Net Income$615M+62.5%
EPS (Diluted)6.20+62.7%
Gross Margin44.01%+2.0%
EBITDA Margin24.6%-9.8%
Operating Margin15.87%-2.4%
Net Margin11.26%+53.0%
ROE9.51%+55.9%
ROIC7.17%+6.4%
Debt/Equity0.33-37.9%
Interest Coverage10.05+73.5%

Analysis→Technical→

STE Key Insights

STERIS plc (STE) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓14 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 12.5%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

STE Price & Volume

STERIS plc (STE) stock price & volume — 10-year historical chart

Loading chart...

STE Growth Metrics

STERIS plc (STE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years11.43%

5 Years12.49%

3 Years8.93%

TTM14.38%

Profit CAGR

10 Years16.36%

5 Years8.56%

3 Years36.09%

TTM51.37%

EPS CAGR

10 Years10.67%

5 Years5.43%

3 Years35.72%

TTM52.36%

Return on Capital

10 Years8.05%

5 Years8.18%

3 Years8.35%

Last Year9%

STE Recent Earnings

STERIS plc (STE) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)

Q1 2026Latest

Feb 4, 2026

EPS

$2.53

Est $2.53

+0.0%

Revenue

$1.5B

Est $1.5B

+1.0%

Q4 2025

Nov 5, 2025

EPS

$2.47

Est $2.35

+5.1%

Revenue

$1.5B

Est $1.4B

+2.0%

Q3 2025

Aug 6, 2025

EPS

$2.34

Est $2.26

+3.5%

Revenue

$1.4B

Est $1.4B

+2.1%

Q2 2025

May 14, 2025

EPS

$2.74

Est $2.60

+5.4%

Revenue

$1.5B

Est $1.5B

+0.8%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 4, 2026	$2.53vs $2.53+0.0%	$1.5Bvs $1.5B+1.0%
Q4 2025	Nov 5, 2025	$2.47vs $2.35+5.1%	$1.5Bvs $1.4B+2.0%
Q3 2025	Aug 6, 2025	$2.34vs $2.26+3.5%	$1.4Bvs $1.4B+2.1%
Q2 2025	May 14, 2025	$2.74vs $2.60+5.4%	$1.5Bvs $1.5B+0.8%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
WATWaters CorporationDirect Competitor	22.78B	349.53	32.48	6.99%	11.91%	8.04%	0.55
MMSIMerit Medical Systems, Inc.Direct Competitor	3.68B	61.63	28.93	11.66%	9.03%	8.95%	0.57
HSICHenry Schein, Inc.Direct Competitor	8.31B	72.44	22.15	4.03%	3.02%	8.24%	0.77
IARTIntegra LifeSciences Holdings CorporationDirect Competitor	1.09B	14.00	-2.08	1.53%	-30.15%	-47.65%	1.95
CNMDCONMED CorporationDirect Competitor	1.15B	37.32	24.72	5.16%	4%	5.4%	0.81
SHCSotera Health CompanyProduct Competitor	4.51B	15.80	58.52	5.74%	9.91%	20.57%	3.75
BDXBecton, Dickinson and CompanyProduct Competitor	52.45B	144.76	24.83	8.23%	8.01%	6.93%	0.76
BAXBaxter International Inc.Product Competitor	8.77B	16.98	-9.70	5.72%	-9.7%	-16.5%	1.64

Compare STE vs Peers

STERIS plc (STE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs WAT

Most directly comparable listed peer for STE.

Scale Benchmark

vs TMO

Larger-name benchmark to compare STE against a more recognizable public peer.

Peer Set

Compare Top 5

vs WAT, MMSI, HSIC, IART

STE Income Statement

STERIS plc (STE) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Sales/Revenue	2.61B	2.62B	2.78B	3.03B	3.11B	4.22B	4.54B	5.14B	5.46B	5.83B
Revenue Growth %	16.71%	0.28%	6.19%	8.94%	2.53%	35.91%	7.41%	13.28%	6.24%	14.38%
Cost of Goods Sold	1.59B	1.53B	1.61B	1.71B	1.76B	2.34B	2.56B	2.92B	3.06B	3.26B
COGS % of Revenue	60.72%	58.29%	57.77%	56.45%	56.78%	55.41%	56.34%	56.83%	55.99%	-
Gross Profit	1.03B▲ 0%	1.09B▲ 6.5%	1.17B▲ 7.5%	1.32B▲ 12.3%	1.34B▲ 1.8%	1.88B▲ 40.2%	1.98B▲ 5.2%	2.22B▲ 12.0%	2.4B▲ 8.3%	2.57B▲ 0%
Gross Margin %	39.28%	41.71%	42.23%	43.55%	43.22%	44.59%	43.66%	43.17%	44.01%	44.11%
Gross Profit Growth %	14.6%	6.48%	7.53%	12.34%	1.75%	40.2%	5.19%	11.99%	8.32%	-
Operating Expenses	800.01M	692.86M	763.96M	782.95M	794.73M	1.41B	1.19B	1.38B	1.54B	1.57B
OpEx % of Revenue	30.62%	26.45%	27.46%	25.83%	25.57%	33.27%	26.22%	26.89%	28.14%	-
Selling, General & Admin	682.04M	631.98M	669.94M	716.73M	731.32M	1.32B	1.09B	1.25B	1.33B	1.39B
SG&A % of Revenue	26.1%	24.12%	24.08%	23.65%	23.53%	31.22%	24.04%	24.37%	24.44%	-
Research & Development	59.4M	60.78M	63.04M	65.55M	66.33M	86.66M	98.48M	103.68M	107.65M	111.79M
R&D % of Revenue	2.27%	2.32%	2.27%	2.16%	2.13%	2.05%	2.17%	2.02%	1.97%	-
Other Operating Expenses	58.57M	103K	30.99M	673K	-2.91M	48K	485K	26.05M	94.2M	3.4M
Operating Income	226.21M▲ 0%	399.88M▲ 76.8%	411.02M▲ 2.8%	537.05M▲ 30.7%	548.37M▲ 2.1%	477.81M▼ 12.9%	791.1M▲ 65.6%	836.12M▲ 5.7%	866.64M▲ 3.7%	1B▲ 0%
Operating Margin %	8.66%	15.26%	14.77%	17.72%	17.65%	11.31%	17.44%	16.27%	15.87%	17.18%
Operating Income Growth %	6.24%	76.78%	2.79%	30.66%	2.11%	-12.87%	65.57%	5.69%	3.65%	-
EBITDA	414.35M	578.22M	636.95M	734.28M	767.61M	1.03B	1.34B	1.4B	1.34B	1.36B
EBITDA Margin %	15.86%	22.07%	22.89%	24.23%	24.7%	24.41%	29.63%	27.27%	24.6%	23.38%
EBITDA Growth %	16.17%	39.55%	10.16%	15.28%	4.54%	34.3%	30.37%	4.27%	-4.17%	-1.53%
D&A (Non-Cash Add-back)	188.14M	178.33M	225.92M	197.24M	219.24M	553.1M	552.9M	565.24M	476.21M	363.45M
EBIT	229.17M	405.61M	414.04M	539.03M	554.71M	456.29M	791.1M	847.16M	882.47M	999.43M
Net Interest Income	-41.56M	-44.9M	-41.99M	-38.29M	-30.84M	-83.21M	-110.83M	-133.31M	-77.86M	-55.58M
Interest Income	2.96M	5.73M	3.02M	1.99M	6.34M	6.28M	0	11.04M	8.4M	7.13M
Interest Expense	44.52M	50.63M	45.02M	40.28M	37.18M	89.49M	110.83M	144.35M	86.26M	62.72M
Other Income/Expense	-41.56M	-44.9M	-41.99M	-38.29M	-30.84M	-111.01M	-110.83M	-133.31M	-70.43M	-61.04M
Pretax Income	184.65M▲ 0%	354.98M▲ 92.3%	369.03M▲ 4.0%	498.75M▲ 35.2%	517.53M▲ 3.8%	366.8M▼ 29.1%	680.27M▲ 85.5%	702.81M▲ 3.3%	796.21M▲ 13.3%	940.11M▲ 0%
Pretax Margin %	7.07%	13.55%	13.26%	16.46%	16.65%	8.69%	15%	13.68%	14.58%	16.13%
Income Tax	74.02M	63.36M	64.28M	90.89M	120.66M	82.34M	124.07M	149.53M	184.65M	229.95M
Effective Tax Rate %	40.08%	17.85%	17.42%	18.22%	23.32%	22.45%	18.24%	21.28%	23.19%	24.46%
Net Income	109.97M▲ 0%	290.92M▲ 164.6%	304.05M▲ 4.5%	407.66M▲ 34.1%	397.4M▼ 2.5%	243.89M▼ 38.6%	107.03M▼ 56.1%	378.24M▲ 253.4%	614.64M▲ 62.5%	707.77M▲ 0%
Net Margin %	4.21%	11.1%	10.93%	13.45%	12.79%	5.77%	2.36%	7.36%	11.26%	12.14%
Net Income Growth %	-0.72%	164.55%	4.52%	34.08%	-2.52%	-38.63%	-56.12%	253.4%	62.5%	51.37%
Net Income (Continuing)	110.63M	291.62M	305.08M	407.86M	396.87M	284.46M	556.2M	553.28M	611.56M	710.16M
Discontinued Operations	0	0	0	0	0	-41.59M	-450.38M	-173.2M	4.52M	-786K
Minority Interest	11.43M	11.34M	7.99M	12.85M	10.48M	12.28M	9.97M	13.18M	12.35M	0
EPS (Diluted)	1.28▲ 0%	3.39▲ 164.8%	3.56▲ 5.0%	4.76▲ 33.7%	4.63▼ 2.7%	2.48▼ 46.4%	1.07▼ 56.9%	3.81▲ 256.1%	6.20▲ 62.7%	7.16▲ 0%
EPS Growth %	-17.95%	164.84%	5.01%	33.71%	-2.73%	-46.44%	-56.85%	256.07%	62.73%	52.36%
EPS (Basic)	1.29	3.42	3.59	4.81	4.66	2.50	1.07	3.83	6.24	-
Diluted Shares Outstanding	86.09M	85.71M	85.47M	85.64M	85.9M	98.33M	100.25M	99.36M	99.07M	98.8M
Basic Shares Outstanding	85.47M	85.03M	84.58M	84.78M	85.2M	97.53M	99.71M	98.79M	98.58M	98.3M
Dividend Payout Ratio	84.75%	35.38%	37%	30.18%	33.68%	66.9%	171.45%	53.03%	35.77%	-

STE Balance Sheet

STERIS plc (STE) balance sheet — assets, liabilities & shareholders' equity

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Total Current Assets	1.02B	989.66M	1.05B	1.22B	1.21B	1.88B	2.01B	2.87B	2B	2.29B
Cash & Short-Term Investments	282.92M	201.53M	220.63M	319.58M	220.53M	348.32M	208.36M	207.02M	171.7M	423.7M
Cash Only	282.92M	201.53M	220.63M	319.58M	220.53M	348.32M	208.36M	207.02M	171.7M	423.7M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	483.45M	528.07M	564.83M	586.48M	609.41M	799.04M	864.99M	1.01B	1.04B	990.6M
Days Sales Outstanding	67.54	73.57	74.1	70.63	71.58	69.06	69.6	71.62	69.79	61.52
Inventory	197.84M	205.73M	208.24M	263.54M	315.07M	575M	604.41M	674.53M	581.33M	673.5M
Days Inventory Outstanding	45.51	49.17	47.29	56.22	65.18	89.67	86.33	84.3	69.42	71.56
Other Current Assets	0	0	0	0	0	0	154.41M	979.25M	203.77M	198.4M
Total Non-Current Assets	3.91B	4.21B	4.02B	4.22B	5.36B	9.54B	8.81B	8.19B	8.15B	8.31B
Property, Plant & Equipment	915.91M	1.01B	1.03B	1.24B	1.39B	1.74B	1.8B	1.94B	2.11B	2.29B
Fixed Asset Turnover	2.85x	2.59x	2.70x	2.44x	2.24x	2.43x	2.52x	2.65x	2.58x	2.63x
Goodwill	2.23B	2.43B	2.32B	2.36B	3.03B	4.4B	3.88B	4.07B	4.1B	4.23B
Intangible Assets	724.89M	726.98M	604.61M	565.47M	898.41M	3.33B	2.08B	2.12B	1.85B	1.69B
Long-Term Investments	0	0	0	0	0	0	0	0	14.3M	16M
Other Non-Current Assets	34.55M	39.39M	60.21M	51.58M	52.72M	70.66M	1.06B	66.2M	68.75M	337.25M
Total Assets	4.92B▲ 0%	5.2B▲ 5.6%	5.07B▼ 2.4%	5.44B▲ 7.2%	6.57B▲ 20.8%	11.42B▲ 73.8%	10.82B▼ 5.3%	11.06B▲ 2.2%	10.15B▼ 8.3%	10.59B▲ 0%
Asset Turnover	0.53x	0.50x	0.55x	0.56x	0.47x	0.37x	0.42x	0.46x	0.54x	0.56x
Asset Growth %	-7.89%	5.6%	-2.45%	7.25%	20.84%	73.76%	-5.27%	2.23%	-8.29%	2.12%
Total Current Liabilities	381.58M	398.46M	465.2M	503.61M	577.92M	922.22M	861.84M	931.13M	1.02B	922.3M
Accounts Payable	133.48M	135.87M	152.91M	149.34M	156.95M	225.74M	264.17M	251.72M	280.77M	285.1M
Days Payables Outstanding	30.71	32.47	34.73	31.86	32.47	35.21	37.73	31.46	33.53	32.93
Short-Term Debt	0	0	0	0	0	142.88M	60M	85.94M	125M	0
Deferred Revenue (Current)	71.02M	31.62M	55.33M	53.3M	62.49M	110.79M	85.73M	70.46M	57.5M	158.8M
Other Current Liabilities	139.46M	207.6M	219.01M	243.94M	271.39M	323.65M	331.69M	418.35M	447.01M	637.2M
Current Ratio	2.67x	2.48x	2.27x	2.43x	2.10x	2.04x	2.33x	3.08x	1.96x	1.96x
Quick Ratio	2.15x	1.97x	1.82x	1.91x	1.55x	1.41x	1.63x	2.36x	1.39x	1.39x
Cash Conversion Cycle	82.34	90.26	86.67	94.99	104.29	123.53	118.2	124.46	105.68	100.14
Total Non-Current Liabilities	1.73B	1.58B	1.42B	1.52B	2.11B	3.96B	3.87B	3.82B	2.51B	2.5B
Long-Term Debt	1.48B	1.32B	1.18B	1.15B	1.65B	2.95B	3.02B	3.12B	1.92B	0
Capital Lease Obligations	0	0	0	114.11M	129.67M	155.06M	139.56M	145.83M	124.64M	381.04M
Deferred Tax Liabilities	171.81M	159.97M	151.04M	164.07M	236.86M	780.62M	617.54M	479.69M	403.65M	1.23B
Other Non-Current Liabilities	82.67M	108.6M	87.81M	90.35M	88.01M	75.58M	97.07M	71.55M	61.89M	2.69B
Total Liabilities	2.11B	1.98B	1.89B	2.02B	2.68B	4.88B	4.73B	4.75B	3.53B	3.42B
Total Debt	1.48B	1.32B	1.18B	1.28B	1.8B	3.28B	3.25B	3.38B	2.2B	0
Net Debt	1.2B	1.11B	962.59M	964.86M	1.58B	2.93B	3.04B	3.18B	2.03B	-423.7M
Debt / Equity	0.53x	0.41x	0.37x	0.38x	0.46x	0.50x	0.53x	0.54x	0.33x	0.33x
Debt / EBITDA	3.57x	2.28x	1.86x	1.75x	2.35x	3.18x	2.42x	2.41x	1.64x	0.00x
Net Debt / EBITDA	2.89x	1.93x	1.51x	1.31x	2.06x	2.84x	2.26x	2.27x	1.51x	1.51x
Interest Coverage	5.08x	7.90x	9.13x	13.33x	14.75x	5.34x	7.14x	5.79x	10.05x	15.94x
Total Equity	2.81B▲ 0%	3.22B▲ 14.5%	3.19B▼ 1.0%	3.42B▲ 7.3%	3.89B▲ 13.8%	6.54B▲ 68.2%	6.09B▼ 7.0%	6.32B▲ 3.7%	6.62B▲ 4.8%	7.17B▲ 0%
Equity Growth %	-7.53%	14.49%	-0.98%	7.3%	13.85%	68.18%	-6.99%	3.75%	4.76%	31.9%
Book Value per Share	32.64	37.54	37.27	39.91	45.30	66.56	60.72	63.56	66.78	72.55
Total Shareholders' Equity	2.8B	3.21B	3.18B	3.41B	3.88B	6.53B	6.08B	6.3B	6.6B	7.17B
Common Stock	2.09B	2.05B	2B	1.98B	2B	4.74B	4.49B	4.54B	4.42B	0
Retained Earnings	954.15M	1.15B	1.34B	1.66B	1.94B	2B	1.91B	2.09B	2.48B	0
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-240.7M	11.69M	-159.78M	-235.46M	-61.24M	-209.81M	-320.71M	-328.66M	-292.34M	0
Minority Interest	11.43M	11.34M	7.99M	12.85M	10.48M	12.28M	9.97M	13.18M	12.35M	0

STE Cash Flow Statement

STERIS plc (STE) cash flow — operating, investing & free cash flow history

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Cash from Operations	424.09M	457.63M	539.5M	590.56M	689.64M	684.81M	756.95M	973.27M	1.15B	1.15B
Operating CF Margin %	16.23%	17.47%	19.39%	19.48%	22.19%	16.21%	16.69%	18.94%	21.03%	-
Operating CF Growth %	66.52%	7.91%	17.89%	9.46%	16.78%	-0.7%	10.53%	28.58%	17.96%	45%
Net Income	110.63M	291.62M	304.75M	407.86M	396.87M	242.87M	105.81M	380.08M	616.07M	707.77M
Depreciation & Amortization	188.14M	178.33M	225.92M	197.24M	219.24M	553.1M	552.9M	565.24M	476.21M	122.35M
Stock-Based Compensation	18.79M	22.19M	23.96M	23.81M	25.97M	57.66M	38.95M	56.53M	57.4M	9.79M
Deferred Taxes	31.27M	-24.72M	-6.62M	9.44M	4.24M	-106.62M	-185.91M	-131.41M	-76.55M	-52.76M
Other Non-Cash Items	132.45M	49.36M	-18.84M	2.02M	24.32M	87.07M	495.22M	248.91M	8.43M	458.26M
Working Capital Changes	-57.2M	-59.15M	10.34M	-49.81M	19.01M	-149.28M	-250.02M	-146.08M	66.51M	18.27M
Change in Receivables	-48.14M	-37.73M	-48.49M	-17.87M	12.08M	-51.97M	-133.3M	-128.07M	-28.82M	-108.11M
Change in Inventory	-12.83M	-5.18M	-14.18M	-39.14M	3.77M	-102.92M	-123.92M	-37.45M	73.07M	73.8M
Change in Payables	6.88M	563K	21.24M	-2.78M	-7.21M	14.89M	53.34M	-18.96M	33.59M	41.09M
Cash from Investing	-104.25M	-203.83M	-213.22M	-319.74M	-1.15B	-666.56M	-383.33M	-887.36M	388.77M	-365.1M
Capital Expenditures	-172.9M	-165.46M	-189.72M	-214.52M	-239.26M	-287.56M	-361.97M	-360.33M	-370.09M	-349.69M
CapEx % of Revenue	6.62%	6.32%	6.82%	7.08%	7.7%	6.81%	7.98%	7.01%	6.78%	-
Acquisitions	70.16M	-37.38M	-10.84M	-109.38M	-908.67M	-380.74M	-35.95M	-536.8M	760.42M	-17.46M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	4.85M	-989K	-13.29M	4.16M	-1.82M	1.74M	14.59M	7.38M	9.2M	8.84M
Cash from Financing	-267.1M	-356.18M	-294.79M	-163.15M	345.62M	115.83M	-498.72M	-85.19M	-1.57B	-648.37M
Debt Issued (Net)	-75.38M	-193.44M	-112.09M	-26.5M	484.54M	372.18M	-6.22M	121.49M	-1.16B	-287.11M
Equity Issued (Net)	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1.26M
Dividends Paid	-93.19M	-102.93M	-112.5M	-123.03M	-133.84M	-163.17M	-183.5M	-200.57M	-219.88M	-236.01M
Share Repurchases	-97.51M	-65.48M	-81.49M	-51.24M	-14.65M	-55.78M	-308.56M	-11.77M	-211.32M	-263K
Other Financing	-1.01M	5.67M	11.29M	37.63M	9.56M	-37.41M	-437K	5.66M	23.26M	-124.99M
Net Change in Cash	34.08M▲ 0%	-81.38M▼ 338.8%	19.1M▲ 123.5%	98.95M▲ 418.1%	-99.05M▼ 200.1%	127.79M▲ 229.0%	-139.96M▼ 209.5%	-1.34M▲ 99.0%	-35.32M▼ 2541.7%	268.52M▲ 0%
Free Cash Flow	251.19M▲ 0%	292.18M▲ 16.3%	349.79M▲ 19.7%	376.04M▲ 7.5%	450.38M▲ 19.8%	397.25M▼ 11.8%	394.98M▼ 0.6%	612.95M▲ 55.2%	778M▲ 26.9%	917.1M▲ 0%
FCF Margin %	9.61%	11.15%	12.57%	12.41%	14.49%	9.41%	8.71%	11.93%	14.25%	15.74%
FCF Growth %	95.83%	16.32%	19.72%	7.51%	19.77%	-11.8%	-0.57%	55.19%	26.93%	22.05%
FCF per Share	2.92	3.41	4.09	4.39	5.24	4.04	3.94	6.17	7.85	7.85
FCF Conversion (FCF/Net Income)	3.86x	1.57x	1.77x	1.45x	1.74x	2.81x	7.07x	2.57x	1.87x	1.30x
Interest Paid	42.8M	48.66M	0	0	0	84.7M	108.47M	142.17M	89.4M	0
Taxes Paid	78.01M	85.63M	0	0	0	138.38M	254.66M	271.27M	273.61M	0

STE Key Ratios

STERIS plc (STE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	3.76%	9.65%	9.5%	12.35%	10.87%	4.67%	1.69%	6.1%	9.51%	9.87%
Return on Invested Capital (ROIC)	4.06%	7.19%	7.27%	9.44%	8.34%	4.79%	6.38%	6.74%	7.17%	7.17%
Gross Margin	39.28%	41.71%	42.23%	43.55%	43.22%	44.59%	43.66%	43.17%	44.01%	44.11%
Net Margin	4.21%	11.1%	10.93%	13.45%	12.79%	5.77%	2.36%	7.36%	11.26%	12.14%
Debt / Equity	0.53x	0.41x	0.37x	0.38x	0.46x	0.50x	0.53x	0.54x	0.33x	0.33x
Interest Coverage	5.08x	7.90x	9.13x	13.33x	14.75x	5.34x	7.14x	5.79x	10.05x	15.94x
FCF Conversion	3.86x	1.57x	1.77x	1.45x	1.74x	2.81x	7.07x	2.57x	1.87x	1.30x
Revenue Growth	16.71%	0.28%	6.19%	8.94%	2.53%	35.91%	7.41%	13.28%	6.24%	14.38%

STE SEC Filings & Documents

STERIS plc (STE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 6, 2026·SEC

Material company update

Feb 4, 2026·SEC

Material company update

Nov 5, 2025·SEC

10-K Annual Reports

FY 2025

May 29, 2025·SEC

FY 2024

May 29, 2024·SEC

10-Q Quarterly Reports

FY 2026

Feb 6, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

STE Frequently Asked Questions

STERIS plc (STE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

STERIS plc (STE) reported $5.83B in revenue for fiscal year 2025. This represents a 990% increase from $534.6M in 1996.

STERIS plc (STE) grew revenue by 6.2% over the past year. This is steady growth.

Yes, STERIS plc (STE) is profitable, generating $707.8M in net income for fiscal year 2025 (11.3% net margin).

Dividend & Returns

Yes, STERIS plc (STE) pays a dividend with a yield of 1.03%. This makes it attractive for income-focused investors.

STERIS plc (STE) has a return on equity (ROE) of 9.5%. This is below average, suggesting room for improvement.

STERIS plc (STE) generated $917.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More STE

STERIS plc (STE) financial analysis — history, returns, DCA and operating performance tools

Full STE Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

STERIS plc(STE)Earnings, Financials & Key Ratios

STE Key Insights

✓Strengths

✗Weaknesses

STE Price & Volume

STE Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

STE Recent Earnings

STE Peer Comparison

Compare STE vs Peers

vs WAT

vs TMO

Compare Top 5

STE Income Statement

STE Balance Sheet

STE Cash Flow Statement

STE Key Ratios

STE SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

STE Frequently Asked Questions

Explore More STE

Full STE Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation